Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future?

  • Authors : Neuen BL; George Institute for Global Health, University of New South Wales Sydney, Sydney, Australia.; Jardine MJ

Subjects: Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*drug therapy ; Kidney/Kidney/Kidney/*drug effects ; Renal Insufficiency, Chronic/Renal Insufficiency, Chronic/Renal Insufficiency, Chronic/*prevention & control

  • Source: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association [Nephrol Dial Transplant] 2020 Jan 01; Vol. Publisher: Oxford University Press Country of Publication: England NLM ID: 8706402 Publication Model: Print Cited Medium:

Record details

×
Academic Journal

Renal physiology of glucose handling and therapeutic implications.

  • Authors : Cherney DZ; Toronto General Hospital Research Institute, UHN, Toronto, ON, Canada.; Department of Physiology and Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.

Subjects: Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*drug therapy ; Glucose/Glucose/Glucose/*metabolism ; Hypoglycemic Agents/Hypoglycemic Agents/Hypoglycemic Agents/*pharmacology

  • Source: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association [Nephrol Dial Transplant] 2020 Jan 01; Vol. Publisher: Oxford University Press Country of Publication: England NLM ID: 8706402 Publication Model: Print Cited Medium:

Record details

×
Academic Journal

Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trial.

  • Authors : Heerspink HJL; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.; The George Institute for Global Health, Sydney, New South Wales, Australia.

Subjects: Benzhydryl Compounds* ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Glucosides*

  • Source: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association [Nephrol Dial Transplant] 2024 Feb 28; Vol. Publisher: Oxford University Press Country of Publication: England NLM ID: 8706402 Publication Model: Print Cited Medium:

Record details

×
Academic Journal

Renal outcomes after contrast exposure in patients with diabetes who use sodium-glucose cotransporter 2 inhibitors.

  • Authors : Chen CW; Division of Cardiology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, 110, Taiwan.; Division of Cardiology, Department of Internal Medicine and Cardiovascular Research Center, Taipei Medical University Hospital, Taipei, 110, Taiwan.

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/epidemiology ; Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/adverse effects

  • Source: Postgraduate medical journal [Postgrad Med J] 2024 Feb 15; Vol. 100 (1181), pp. 142-150.Publisher: Oxford University Press Country of Publication: England NLM ID: 0234135 Publication Model: Print Cited Medium:

Record details

×
Academic Journal

SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA.

  • Authors : Sarafidis P; Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.; Ferro CJ

Subjects: Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*complications ; Glucagon-Like Peptide-1 Receptor/Glucagon-Like Peptide-1 Receptor/Glucagon-Like Peptide-1 Receptor/*agonists ; Heart Diseases/Heart Diseases/Heart Diseases/*prevention & control

  • Source: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association [Nephrol Dial Transplant] 2019 Feb 01; Vol. Publisher: Oxford University Press Country of Publication: England NLM ID: 8706402 Publication Model: Print Cited Medium:

Record details

×
Academic Journal

The sodium glucose co-transporter 2 inhibitor dapagliflozin ameliorates the fluid-retaining effect of the endothelin A receptor antagonist zibotentan.

  • Authors : Veenit V; Bioscience Renal, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Heerspink HJL

Subjects: Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/pharmacology ; Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/therapeutic use ; Renal Insufficiency, Chronic*

  • Source: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association [Nephrol Dial Transplant] 2023 Sep 29; Vol. Publisher: Oxford University Press Country of Publication: England NLM ID: 8706402 Publication Model: Print Cited Medium:

Record details

×
Academic Journal

SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA.

  • Authors : Mark PB; School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.; Sarafidis P

Subjects: Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/therapeutic use ; Renal Insufficiency, Chronic* ; Cardiovascular Diseases*/Cardiovascular Diseases*/Cardiovascular Diseases*/etiology

  • Source: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association [Nephrol Dial Transplant] 2023 Oct 31; Vol. Publisher: Oxford University Press Country of Publication: England NLM ID: 8706402 Publication Model: Print Cited Medium:

Record details

×
Academic Journal

Differential effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes according to renal function: a dose-response meta-analysis involving 10 randomized clinical trials and 71 553 individuals.

  • Authors : Lin DS; Division of Cardiology, Department of Internal Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei 111, Taiwan.; Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei 100, Taiwan.

Subjects: Atherosclerosis* ; Cardiovascular Diseases*/Cardiovascular Diseases*/Cardiovascular Diseases*/epidemiology ; Cardiovascular Diseases*/Cardiovascular Diseases*/Cardiovascular Diseases*/prevention & control

  • Source: European journal of endocrinology [Eur J Endocrinol] 2023 Jul 20; Vol. 189 (1), pp. S17-S25.Publisher: Oxford University Press Country of Publication: England NLM ID: 9423848 Publication Model: Print Cited Medium:

Record details

×
Academic Journal

Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis.

  • Authors : McEwan P; Health Economics and Outcomes Research Ltd, Cardiff, UK.; Boyce R

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/complications ; Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/adverse effects ; Renal Insufficiency, Chronic*/Renal Insufficiency, Chronic*/Renal Insufficiency, Chronic*/complications

  • Source: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association [Nephrol Dial Transplant] 2023 May 04; Vol. Publisher: Oxford University Press Country of Publication: England NLM ID: 8706402 Publication Model: Print Cited Medium:

Record details

×
Academic Journal

Overcoming barriers to implementing new guideline-directed therapies for chronic kidney disease.

  • Authors : Nee R; Nephrology Service, Walter Reed National Military Medical Center, Bethesda, MD, USA.; Department of Medicine, Uniformed Services University, Bethesda, MD, USA.

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/therapeutic use ; Renal Insufficiency, Chronic*/Renal Insufficiency, Chronic*/Renal Insufficiency, Chronic*/therapy

  • Source: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association [Nephrol Dial Transplant] 2023 Feb 28; Vol. Publisher: Oxford University Press Country of Publication: England NLM ID: 8706402 Publication Model: Print Cited Medium:

Record details

×
  • 1-10 of  153 results for ""Sodium-Glucose Transporter 2 Inhibitors""